Sumitomo nets Myovant in $2.9B buyout, adding IVF asset to pipeline

Sumitomo has landed its takeover target. After seeing Myovant turn down its original offer, the Japanese drugmaker has added almost 20% to its price to get the deal done and snag a phase 2 in vitro fertilization asset.